Conference
Phase II Clinical Trial of Bevacizumab and Low-Dose Metronomic Oral Cyclophosphamide in Recurrent Ovarian Cancer: A Trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia
Abstract
PURPOSE: Vascular endothelial growth factor (VEGF) plays an important role in the biology of ovarian cancer (OC). Inhibitors of VEGF suppress tumor growth in OC models. Metronomic chemotherapy, defined as frequent administration of low doses of cytotoxic chemotherapy, suppresses tumor growth, possibly by inhibiting angiogenesis. A phase II trial was conducted to evaluate the antitumor activity and adverse effects of bevacizumab and metronomic …
Authors
Garcia AA; Hirte H; Fleming G; Yang D; Tsao-Wei DD; Roman L; Groshen S; Swenson S; Markland F; Gandara D
Volume
26
Pagination
pp. 76-82
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
January 1, 2008
DOI
10.1200/jco.2007.12.1939
Conference proceedings
Journal of Clinical Oncology
Issue
1
ISSN
0732-183X
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AdenocarcinomaAdministration, OralAdultAgedAged, 80 and overAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBevacizumabCaliforniaChicagoCyclophosphamideCystadenocarcinoma, SerousE-SelectinFemaleHumansMiddle AgedNeoplasm Recurrence, LocalOvarian NeoplasmsPeritoneal NeoplasmsPrognosisSurvival RateThrombospondin 1Treatment OutcomeVascular Endothelial Growth Factor A